Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boceprevir Hep C Response-Guided Therapy Works For Experienced Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

About half of experienced patients made enough progress to get into the shortened therapy group, and among them the cure rate was 86%.

You may also be interested in...



Dual FDA Advisory Committee Reviews Shaping Up To Be A Showdown For Dueling Merck And Vertex Hepatitis C Drugs

Approval is widely assumed for both boceprevir and telaprevir, but there is still much to be discussed about the devilish details. Additional data coming out at European liver meeting should also be informative.

Dual FDA Advisory Committee Reviews Shaping Up To Be A Showdown For Dueling Merck And Vertex Hepatitis C Drugs

Approval is widely assumed for both boceprevir and telaprevir, but there is still much to be discussed about the devilish details. Additional data coming out at European liver meeting should also be informative.

Vertex, Merck Face Education Challenge With Complex Hep C Regimens

With two direct acting antivirals now pending at FDA, the hepatitis C community is excited about adding efficacious new drugs to standard of care. But the regimens aren't as simple as that sounds; once the therapies are approved, the sponsors will have a considerable education effort on their hands, as physicians and patients work their way through the new HCV treatment calculus.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel